Related Experiment Videos
Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion
Angela M Domitrovich1, Daniel J Felmlee, Aleem Siddiqui
1Department of Medicine, Moores Cancer Center, University of California at San Diego, La Jolla, California 92093-0803, USA.
The Journal of Biological Chemistry
|October 6, 2005
Summary
Hepatitis C virus (HCV) disrupts liver lipid metabolism by reducing apolipoprotein B100 (apoB100) secretion. This study reveals HCV
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Hepatitis C virus (HCV) infection alters host lipid metabolism.
- Lipid metabolism is crucial for lipoprotein synthesis and export from the liver.
Purpose of the Study:
- To investigate the impact of HCV on apolipoprotein B100 (apoB100) secretion.
- To elucidate the mechanisms by which HCV affects lipid metabolism and apoB100 metabolism.
Main Methods:
- Utilized the HCV subgenomic replicon expression system.
- Assessed apoB100 secretion and degradation.
- Measured triglyceride levels and microsomal triglyceride transfer protein (MTTP) mRNA and activity.
Main Results:
- HCV infection significantly reduced apoB100 secretion.
- Inhibition of apoB100 degradation did not restore secretion.
- Triglyceride levels and MTTP mRNA/activity were decreased in HCV replicon-expressing cells.
- Evidence suggests interaction between HCV nonstructural protein 5A and apoB100.
Conclusions:
- HCV infection impairs apoB100 secretion, contributing to altered lipid metabolism.
- Reduced triglyceride synthesis and MTTP activity are implicated in HCV-induced lipid dysregulation.
- HCV nonstructural protein 5A may play a role in modulating apoB100 metabolism.